We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ATOS Atossa Therapeutics Inc

0.0499 (3.70%)
Apr 18 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 2,324,428
Bid Price 1.39
Ask Price 1.40
News -
Day High 1.48


52 Week Range


Day Low 1.24
Share Name Share Symbol Market Stock Type
Atossa Therapeutics Inc ATOS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.0499 3.70% 1.3999 18:50:07
Open Price Low Price High Price Close Price Previous Close
1.31 1.24 1.48 1.42 1.35
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
8,009 2,324,428 US$ 1.39 US$ 3,224,962 - 0.5901 - 2.31
Last Trade Type Quantity Price Currency
18:50:07 formt 114 US$ 1.3999 USD

Atossa Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
176.68M 125.30M - 0 -26.96M -0.22 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Atossa Therapeutics News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ATOS Message Board. Create One! See More Posts on ATOS Message Board See More Message Board Posts

Historical ATOS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.771.841.241.542,063,465-0.3701-20.91%
1 Month1.652.311.241.803,100,652-0.2501-15.16%
3 Months0.812.310.77441.591,650,8900.589972.83%
6 Months0.702.310.621.43966,7690.699999.99%
1 Year0.742.310.59011.24823,7690.659989.18%
3 Years1.639.800.503.753,351,469-0.2301-14.12%
5 Years2.629.800.503.193,511,140-1.22-46.57%

Atossa Therapeutics Description

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Your Recent History

Delayed Upgrade Clock